ABSTRACT
OBJECTIVE: Lanoteplase is a rationally designed variant of tissue plasminogen activator. The aim of this study was to examine the pharmacokinetics and functional activity of a single intravenous bolus dose of lanoteplase with those of a bolus plus two-step infusion of alteplase. DESIGN: Seven-centre substudy of the InTIME-I angiographic trial in patients presenting within 6 hours of onset of suspected acute myocardial infarction. PATIENTS AND PARTICIPANTS: A total of 31 patients (28 males, 3 females) enrolled in this substudy [mean age 59 (range 26 to 76) years]. METHODS: Twenty-three patients randomised to lanoteplase received single bolus doses of 15 kU/kg (n = 5), 30 kU/kg (n = 3), 60 kU/kg (n = 9), or 120 kU/kg (n = 6). Eight patients received alteplase Subject(s)
Fibrinolytic Agents/pharmacokinetics
, Myocardial Infarction/drug therapy
, Tissue Plasminogen Activator/pharmacokinetics
, Adult
, Aged
, Area Under Curve
, Dose-Response Relationship, Drug
, Female
, Fibrinolytic Agents/administration & dosage
, Fibrinolytic Agents/therapeutic use
, Half-Life
, Humans
, Infusions, Intravenous
, Injections, Intravenous
, Male
, Metabolic Clearance Rate
, Middle Aged
, Tissue Plasminogen Activator/administration & dosage
, Tissue Plasminogen Activator/therapeutic use
